In February 2016, the US Food and Drug Administration (FDA) sought advice from the National Academy of Medicine, now part of the National Academies, “to help… develop a regulatory framework for opioid review, approval, and monitoring that balances individual need for pain control with consideration of the broader public health consequences of abuse and misuse.”1(p1482)
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Wolfe SM. The Public Health Urgency of a Temporary FDA Moratorium on New Opioid Approvals. JAMA Intern Med. 2019;179(11):1459–1460. doi:10.1001/jamainternmed.2019.3846
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: